医学
危险系数
放射治疗
置信区间
阶段(地层学)
外科
回顾性队列研究
临床终点
内科学
入射(几何)
累积发病率
比例危险模型
多元分析
癌
队列
随机对照试验
物理
光学
古生物学
生物
作者
Mohamed Shelan,Lukas Anschuetz,Adrian D. Schubert,Beat Bojaxhiu,Alan Dal Pra,Frank Behrensmeier,Daniel M. Aebersold,Roland Giger,Olgun Eliçin
标识
DOI:10.1007/s00066-017-1139-4
摘要
The optimal treatment strategy for stage I-II glottic squamous cell carcinoma (SCC) is not well-defined. This study analyzed treatment results and prognostic factors.This is a single-institution retrospective analysis of 244 patients with T1-2 glottic SCC who underwent normofractionated radiotherapy (RT) and/or surgery between 1990 and 2013. The primary endpoint was relapse-free survival (RFS).Median age was 65 years (range: 36-92 years), the majority (82%) having stage I disease. Definitive RT was used in 82% (median dose: 68 Gy, 2 Gy per fraction). Median follow-up was 59 months. The 5‑year RFS rates were 83 and 75% (p = 0.05) for stage I and 62 and 50% (p = 0.47) for stage II in the RT and surgery groups, respectively. Multivariate analyses indicate T1 vs. T2 and RT vs. surgery as independent prognostic factors for RFS, with hazard ratios of 0.38 (95% confidence interval, CI: 0.21-0.72) and 0.53 (95% CI: 0.30-0.99), respectively (p < 0.05). The 5‑year overall and cause-specific survival rates in the whole cohort were 92 and 96%, respectively, with no significant differences between treatment groups. Anterior commissure involvement was neither a prognostic nor a predictive factor. The incidence of secondary malignancies was not significantly different between patients treated with and without RT (22 vs. 9% at 10 years, respectively, p = 0.18).Despite a possible selection bias, our series demonstrates improved RFS with RT over surgery in stage I glottic SCC.
科研通智能强力驱动
Strongly Powered by AbleSci AI